Skip to content

W. L. Gore & Associates, Inc.

United States US-MF-000001141 Last updated 25 Oct 2026

Devices
2,172
Registries
EUDAMEDFDA
FDA recalls
3226 ongoing

Catalogue2,172

Page 1 of 40

Showing 1-50 of 2,172

EUDAMED certificates9

Held under this manufacturer's EUDAMED registration, grouped by notified body; in force first, then by expiry.

EUDAMED certificates (9)

Notified body 2797 9 certificates

  • MDR 731002 Reissued

    Technical documentation EU MDR

    Issued
    20 Jul 2026
    Expires
    16 Aug 2031
    Valid from
    17 Aug 2026
  • MDR 731175 Reissued

    Technical documentation EU MDR

    Issued
    20 Jul 2026
    Expires
    19 Jul 2031
  • MDR 731176 Reissued

    Technical documentation EU MDR

    Issued
    20 Jul 2026
    Expires
    19 Jul 2031
  • MDR 731178 Reissued

    Technical documentation EU MDR

    Issued
    20 Jul 2026
    Expires
    19 Jul 2031
  • MDR 731181 Reissued

    Technical documentation EU MDR

    Issued
    20 Jul 2026
    Expires
    19 Jul 2031
  • MDR 732281 Reissued

    Technical documentation EU MDR

    Issued
    20 Jul 2026
    Expires
    19 Jul 2031
  • MDR 764343 Supplemented

    Technical documentation EU MDR

    Issued
    20 Aug 2026
    Expires
    26 Apr 2028
    Reason
    Add device or group
  • MDR 732278 Supplemented

    Technical documentation EU MDR

    Issued
    18 Jun 2026
    Expires
    20 Feb 2027
    Reason
    Other
  • MDR 732282 Supplemented

    Technical documentation EU MDR

    Issued
    31 Aug 2026
    Expires
    20 Feb 2027
    Reason
    Change approved

Notified bodies

  • Notified body 2797

FDA recalls32

Recalls this firm reported to the FDA. Device pages show the recalls that name the device or the 510(k)/PMA it was cleared under.

Showing the 10 most recent of 32 recalls.

  • 2026

    • 3 Sep 2026 Z-0158-2027 Not yet classified Ongoing The potential for the devices to be mislabeled with the incorrect length.via FDA establishment W. L. GORE & ASSOCIATES, INC
    • 22 May 2026 Z-2914-2026 Class II Ongoing 10 mm diameter x 7 cm with transmural drainage holes (VSWVH1006) incorrectly labeled as 10 mm diameter x 10 cm length devices without transmural drainage holes (VSWVN1010).via FDA establishment W. L. GORE & ASSOCIATES, INC
    • 22 May 2026 Z-2915-2026 Class II Ongoing 10 mm diameter x 7 cm with transmural drainage holes (VSWVH1006) incorrectly labeled as 10 mm diameter x 10 cm length devices without transmural drainage holes (VSWVN1010).via FDA establishment W. L. GORE & ASSOCIATES, INC
    • 19 May 2026 Z-2672-2026 Class II Ongoing Due to catheter separationvia FDA establishment W. L. GORE & ASSOCIATES, INC
  • 2025

    • 26 Aug 2025 Z-0036-2026 Class II Ongoing Reports of vascular graft delamination, which may lead to reduced access flow; cannulation difficulties; bleeding or bruising; and harms related to reintervention procedures, so Instructions for Use will be updated to modify existing warning to 1) further clarify techniques that may contribute to the risk of delamination, 2) Addition of delamination to device-related adverse event section.via FDA establishment W. L. GORE & ASSOCIATES, INC
  • 2024

    • 3 Jul 2024 Z-2513-2024 Class II Ongoing Devices were labeled with an expiration date of four years and ten days rather than the validated two years.via FDA establishment W. L. GORE & ASSOCIATES, INC
    • 1 Jul 2024 Z-2945-2024 Class II Ongoing Due to packaging defects, sterility assurance and heparin activity may be compromised.via FDA establishment W. L. GORE & ASSOCIATES, INC
    • 1 Jul 2024 Z-2946-2024 Class II Ongoing Due to packaging defects, sterility assurance and heparin activity may be compromised.via FDA establishment W. L. GORE & ASSOCIATES, INC
    • 19 Jan 2024 Z-1179-2024 Class II Ongoing Devices without transmural drainage holes may be mislabeled as devices with transmural drainage holes, or vice versa. Potential health impact includes extending procedure time, unplanned device removal, secondary procedure, cholangitis, cholecystitis, and/or pain. The GORE VIABIL Short Wire Biliary Endoprosthesis is a flexible, self-expanding endoprosthesis designed to maintain luminal patency of the common bile duct which may be obstructed. The endoprosthesis is radially compressed and secured onto the distal end of a catheter-based delivery system for deployment. The catheter provides a means for accessing and implanting the GORE VIABIL Short Wire Biliary Endoprosthesis at the target site in the biliary tract.via FDA establishment W. L. GORE & ASSOCIATES, INC
  • 2022

    • 14 Dec 2022 Z-1048-2023 Class II Ongoing Septal Occluders released with incomplete quality test documentation that assesses the release of the device from the delivery system during the index procedure. A potential failure of this quality test could potentially result could result in occluder embolization, anoxic brain injury, central venous or arterial perforation or rupture.via FDA establishment W. L. GORE & ASSOCIATES, INC
Show the 25 most recent of 32 recalls
  • 2022

    • 21 Sep 2022 Z-0136-2023 Class II Ongoing Due to manufacturing records (Release Test Results) indicating "Failed".via FDA establishment W. L. GORE & ASSOCIATES, INC
  • 2021

    • 7 Sep 2021 Z-0077-2022 Class II Ongoing Incorrect labeling, specifically, expandable endoprosthesis labeled as 8 mm x 59mm x 135 cm, however may contain a 9mm x 29 mm x 135 cm device.via FDA establishment W. L. GORE & ASSOCIATES, INC
    • 2 Sep 2021 Z-0164-2022 Class II Ongoing Septal Occluders contain the incorrect expiration date. Product is labeled with a 3 yr. expiration date instead of 2 yrs.via FDA establishment W. L. GORE & ASSOCIATES, INC
    • 2 Sep 2021 Z-0165-2022 Class II Ongoing Septal Occluders contain the incorrect expiration date. Product is labeled with a 3 yr. expiration date instead of 2 yrs.via FDA establishment W. L. GORE & ASSOCIATES, INC
    • 2 Sep 2021 Z-0166-2022 Class II Ongoing Septal Occluders contain the incorrect expiration date. Product is labeled with a 3 yr. expiration date instead of 2 yrs.via FDA establishment W. L. GORE & ASSOCIATES, INC
    • 2 Sep 2021 Z-0167-2022 Class II Ongoing Septal Occluders contain the incorrect expiration date. Product is labeled with a 3 yr. expiration date instead of 2 yrs.via FDA establishment W. L. GORE & ASSOCIATES, INC
    • 2 Sep 2021 Z-0168-2022 Class II Ongoing Septal Occluders contain the incorrect expiration date. Product is labeled with a 3 yr. expiration date instead of 2 yrs.via FDA establishment W. L. GORE & ASSOCIATES, INC
    • 2 Sep 2021 Z-0169-2022 Class II Ongoing Septal Occluders contain the incorrect expiration date. Product is labeled with a 3 yr. expiration date instead of 2 yrs.via FDA establishment W. L. GORE & ASSOCIATES, INC
    • 2 Sep 2021 Z-0170-2022 Class II Ongoing Septal Occluders contain the incorrect expiration date. Product is labeled with a 3 yr. expiration date instead of 2 yrs.via FDA establishment W. L. GORE & ASSOCIATES, INC
    • 2 Sep 2021 Z-0171-2022 Class II Ongoing Septal Occluders contain the incorrect expiration date. Product is labeled with a 3 yr. expiration date instead of 2 yrs.via FDA establishment W. L. GORE & ASSOCIATES, INC
    • 2 Sep 2021 Z-0172-2022 Class II Ongoing Septal Occluders contain the incorrect expiration date. Product is labeled with a 3 yr. expiration date instead of 2 yrs.via FDA establishment W. L. GORE & ASSOCIATES, INC
    • 12 Jul 2021 Z-2340-2021 Class II Ongoing Complaints received concerning Balloon Catheter leakage from the guidewire lumen and the y-hub during preparation resulting in either insufficient inflation or an inability to inflate.via FDA establishment W. L. GORE & ASSOCIATES, INC
    • 12 May 2021 Z-2292-2021 Class II Ongoing Vascular Grafts containing an inner diameter of 6 mm may be incorrectly labeled as 5 mm and Vascular Grafts containing an inner diameter of 5 mm are incorrectly labeled as 6 mm.via FDA establishment W. L. GORE & ASSOCIATES, INC
    • 12 May 2021 Z-2293-2021 Class II Ongoing Vascular Grafts containing an inner diameter of 6 mm may be incorrectly labeled as 5 mm and Vascular Grafts containing an inner diameter of 5 mm are incorrectly labeled as 6 mm.via FDA establishment W. L. GORE & ASSOCIATES, INC
    • 5 Apr 2021 Z-1593-2021 Class II Terminated The Gore post market surveillance team received a complaint that a GORE VIABIL Biliary Endoprosthesis appeared shorter than the labeled length.via FDA establishment W. L. GORE & ASSOCIATES, INC

FDA establishments1

Registered with the FDA under this company group, matched by name.

  • W. L. Gore & Associates, Inc FLAGSTAFF, AZ · US FEI 2017233

Information

Country
United States(from SRN)
Address
1505, North Fourth Street, Flagstaff, Arizona, United States
Website
wlgore.com
PRRC contact
Tim Raban
EUDAMED SRN
US-MF-000001141
FDA FEI number
3003910212